In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Antiplatelet Agents (Expert Consensus Document on the Use of)

ESC Clinical Practice Guidelines

Acute Coronary Syndromes (ACS)
Cardiovascular Pharmacology and Pharmacotherapy
Guidelines version available to download
Published in2004
ReferenceEuropean Heart Journal (2004) 25, 166–181; doi:10.1016/j.ehj.2003.10.013
Published in2004
  • PDA
  • Published in2004
    ReferenceDownload the PDA version
    Table of contents: Full Text (ESC Clinical Practice Guidelines)
    1. Preamble
    2. Introduction
    3. Platelet pathophysiology
    4. Mechanism of action and clinical efficacy of antiplatelet drugs
    5. Drugs inducing a reversible inhibition of platelet function
    6. Patients that may benefit from antiplatelet therapy
    7. Balance of benefits and risks of antiplatelet therapy
    8. Recommendations concerning individual antiplatelet agents
    9. Areas where we need new trials
    10. Conclusion
    11. Summary
    12. References




    Back to top
    European Society
    of Cardiology

    Les Templiers
    2035 Route des Colles
    CS 80179 BIOT
    06903 Sophia Antipolis
    Cedex France